Page 42 - Demo

Chapter 240References 1. Conroy T, Desseigne F, Ychou M, Bouch%u00e9 O, Guimbaud R, B%u00e9couarn Y, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011;364:1817%u201325. 2. Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcita- bine. N Engl J Med 2013;369:1691%u2013703. 3. Sultana A, Tudur Smith C, Cunningham D, Starling N, Tait D, Neoptole- mos JP, et al. Systematic review, including meta-analyses, on the manage- ment of locally advanced pancreatic cancer using radiation/combined modality therapy. Br J Cancer 2007;96:1183%u201390. 4. Gillen S, Schuster T, Meyer Zum B%u20acuschenfelde C, Friess H, Kleeff J. Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med 2010;7:e1000267. 5. Huguet F, Girard N, Guerche CS-E, Hennequin C, Mornex F, Azria D. Chemoradiotherapy in the management of locally advanced pancreatic carcinoma: a qualitative systematic review. J Clin Oncol 2009;27: 2269%u201377. 6. Chen Y, Sun X-J, Jiang T-H, Mao A-W. Combined radiochemotherapy in patients with locally advanced pancreatic cancer: a meta-analysis. World J Gastroenterol 2013;19:7461%u201371. 7. McGinn CJ, Zalupski MM, Shureiqi I, Robertson JM, Eckhauser FE, Smith DC, et al. Phase I trial of radiation dose escalation with concurrent weekly full-dose gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 2001;19:4202%u20138. 8. Small W, Berlin J, Freedman GM, Lawrence T, Talamonti MS, Mulcahy MF, et al. Full-dose gemcitabine with concurrent radiation therapy in patients with nonmetastatic pancreatic cancer: a multicenter phase II trial. J Clin Oncol 2008;26:942%u20137. 9. Small W, Mulcahy MF, Rademaker A, Bentrem DJ, Benson AB, Weitner BB, et al. Phase II trial of fulldose gemcitabine and bevacizumab in combi- nation with attenuated three-dimensional conformal radiotherapy in 10. Smith JJ, Derynck R, Korc M. Production of transforming growth factor alpha in human pancreatic cancer cells: evidence for a superagonist autocrine cycle. Proc Natl Acad Sci U S A 1987;84:7567%u201370. 11. Kobrin MS, Funatomi H, Friess H, Buchler MW, Stathis P, Korc M. Induction and expression of heparinbinding EGF-like growth factor in human pancreatic cancer. Biochem Biophys Res Commun 1994;202: 1705%u20139. 12. Yamanaka Y, Friess H, Kobrin MS, Buchler M, Beger HG, Korc M. Coex- pression of epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumor aggressiveness. Anti- cancer Res 1993;13:565%u20139. 13. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol Off J Am Soc Clin Oncol 2007;25:1960%u20136. 14. Karapetis CS, Khambata-Ford S, Jonker DJ, O%u2019Callaghan CJ, Tu D, Tebbutt NC, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008;359:1757%u201365. 15. Van Cutsem E, K%u20acohne C-H, L%u00e1ng I, Folprecht G, Nowacki MP, Cascinu S, et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 2011;29:2011%u20139. 16. Berndt C, Haubold K, Wenger F, Brux B, M%u20aculler J, Bendzko P, et al. K-ras mutations in stools and tissue samples from patients with malignant and nonmalignant pancreatic diseases. Clin Chem 1998;44:2103%u20137. 17. Almoguera C, Shibata D, Forrester K, Martin J, Arnheim N, Perucho M. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 1988;53:549%u201354. 18. Cengel KA, Voong KR, Chandrasekaran S, Maggiorella L, Brunner TB, Stanbridge E, et al. Oncogenic K-Ras signals through epidermal growth factor receptor and wild-type H-Ras to promote radiation survival in pancreatic and colorectal carcinoma cells. Neoplasia N Y N 2007;9:341%u20138.